Methods of treating a tumor with an unmethylated mgmt promoter

The method of claim 3, further comprising administering the anti-cancer treatment to the subject who has been identified as being suitable for the anti-cancer treatment.

A method of increasing an anti-tumor immune response in a subject in need thereof, comprising administering to the subject an anti-cancer treatment, wherein the subject has a tumor which comprises an O6-methylguanine-DNA methyltransferase (MGMT) promoter that is unmethylated, and wherein the anti-cancer treatment comprises an interleukin-7 (IL-7) protein. 6 The method of claim 5, comprising, prior to the administering, determining a methylation status of the MGMT promoter in a tumor sample obtained from the subject.

The method of claim 6, wherein, after the administering, the anti-tumor immune response in the subject is increased by at least about 1-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, or at least about 50-fold, as compared to a reference subject (e.g., the subject prior to the administering).

The method of any one of claims 1 to 26, wherein the tumor comprises a glioma. 28 The method of claim 27, wherein the glioma comprises a high-grade glioma (HGG). 29 The method of claim 28, wherein the HGG comprises a glioblastoma (GBM), anaplastic astrocytoma, or both.